Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
The UK thinks weight loss drugs could ease unemployment. Experts say that’s a fantasy
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
Novo Nordisk readies trial results for next-generation weight-loss drug
The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...
Drugmaker Stocks Slide as Trump Taps Vaccine Skeptic RFK Jr for US Health Job
(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...
Medpage Today on MSN1d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart Failure
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
pharmaphorum21h
Lilly's Alzheimer's drug gets UK nod, but no NHS funding
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE.
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...